A pilot study on the association between SLCO1B1 RS4363657 polymorphism and muscle adverse events in adults with newly diagnosed dyslipidaemia who were prescribed a statin: the Malaysian primary health care cohort
- 22 July 2019
- journal article
- research article
- Published by Taylor & Francis in Biomarkers
- Vol. 24 (7) , 659-665
Abstract
Introduction: Statin, the first-line treatment for dyslipidaemia, may have suboptimal adherence due to its associated muscle adverse events. This data however, remains limited. Aim: To determine the association of serum creatine kinase(CK) and SLCO1B1 rs4363657 polymorphism with statin-associated muscle adverse events(SAMAE) among dyslipidaemia participants. Methods: This was a prospective cohort study at government health clinics involving newly diagnosed adults with dyslipidaemia. SAMAE were recorded based on the patient’s complaint after a month on statin. CK was taken at baseline and follow-up. Genetic profiling was performed for SLCO1B1 rs4363657 polymorphism. Results: Among 118 participants, majority were Malay(72%) males(61%) with a mean age of 49 ± 12.2 years old and prescribed lovastatin(61.9). There was a significant association between statin types(lovastatin and simvastatin) and SAMAE(p = 0.0327); no significant association noted between CK and SAMAE(p = 0.5637). The SLCO1B1 rs4363657 polymorphism was significantly associated SAMAE(p < 0.0001). Conclusions: In this first pilot study of a multiethnic Malaysian population, the incidence of SAMAE was 18.6%. SAMAE were significantly higher in subjects on lovastatin compared to simvastatin. SLCO1B1 rs4363657 polymorphism was a significant risk factor for SAMAE.Keywords
This publication has 31 references indexed in Scilit:
- Genetic predisposition to atorvastatin-induced myopathy: a case reportJournal of Clinical Pharmacy and Therapeutics, 2012
- SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic groupBMC Medical Genetics, 2011
- Statin myopathy: A common dilemma not reflected in clinical trialsCleveland Clinic Journal of Medicine, 2011
- Drug-related Myopathies of Which the Clinician Should Be AwareCurrent Rheumatology Reports, 2010
- Risk Factors and Drug Interactions Predisposing to Statin-Induced MyopathyDrug Safety, 2010
- The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side EffectsJACC, 2009
- Pharmacogenomic insights into treatment and management of statin-induced myopathyGenome Medicine, 2009
- Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and PravastatinClinical Pharmacokinetics, 2008
- Genetic determinants of statin intoleranceLipids in Health and Disease, 2007
- A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in MusclePLOS ONE, 2006